如何改进RCHOP作为扩散型大B细胞淋巴瘤的前线治疗方法:对21项随机对照试验的系统审查和元分析
Stergios Intzes1, Marianthi Symeonidou1, Konstantinos Zagoridis1
1Department of Hematology, Medical School, Democritus University of Thrace, Area of Dragana, 68100, Alexandroupolis, PC, Greece.
Annals of hematology
|January 8, 2024
概括
RCHOP是扩散型大b细胞淋巴瘤 (DLBCL) 的标准,但新药添加到RCHOP中显示出无进展生存率 (PFS) 的边际改善. 总体生存数据没有证明实验方案优于RCHOP.
科学领域:
- 血液学 血液学 血液学
- 在瘤学瘤学.
- 临床试验 临床试验
背景情况:
- 扩散性大b细胞淋巴瘤 (DLBCL) 治疗依赖于RCHOP,但大约40%的患者经历了治疗失败.
- 提高RCHOP的疗效仍然是管理DLBCL的关键目标.
结论:
- 虽然RCHOP是DLBCL的标准,但添加新药可以在PFS中带来微小的改善.
- 在间接比较中,没有特定的新药在间接比较中显示出优势.
- 在这次元分析中,与RCHOP相比,实验方案没有显示改善整体存活率.
更多相关视频
06:51Manufacturing Chimeric Antigen Receptor CAR T Cells for Adoptive Immunotherapy
Published on: December 17, 2019
15.1K
06:08Assessment of Chimeric Antigen Receptor T Cell-Associated Toxicities Using an Acute Lymphoblastic Leukemia Patient-Derived Xenograft Mouse Model
Published on: February 10, 2023
1.4K
相关概念视频
02:56Treatment Resistant Cancers
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
02:56Treatment Resistent Cancers
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...